Is the Prostate a Gland? Anatomy, Function & Conditions

The prostate is, without question, a gland. It is a small, walnut-sized organ that sits just below the bladder and wraps around the urethra, and its primary job is to produce a component of seminal fluid that supports sperm survival and motility. What makes the prostate interesting, and what prompts most people to look it up, is not really whether it qualifies as a gland but the remarkable number of ways this one organ can cause trouble as men age.

What Makes the Prostate a Gland

In biological terms, a gland is any organ that produces and releases a substance for use elsewhere in the body. The prostate fits that definition squarely. Its tissue is packed with tiny tubular structures that manufacture a thin, milky fluid rich in enzymes, zinc, citric acid, and proteins like prostate-specific antigen (PSA). During ejaculation, this prostatic fluid mixes with sperm from the testes and fluid from the seminal vesicles to form semen. The prostatic contribution makes up roughly a quarter to a third of total semen volume, and its enzymes play a direct role in liquefying the ejaculate after it leaves the body so sperm can swim freely.

The prostate’s secretory role is shared across all male mammals. Research into evolutionary biology has found that the prostate appeared around 65 million years ago alongside the emergence of mammals themselves, making it one of the defining features of the class.¹ Comparative studies of bat species, for instance, show that even among closely related animals the prostate’s internal structure and secretion patterns vary significantly, suggesting the gland has been subject to strong evolutionary pressures tied to each species’ reproductive strategy.²

The Zones Inside the Prostate

From the outside the prostate looks like a single smooth organ, but internally it is divided into distinct regions that differ in their tissue structure, their disease susceptibility, and even the direction their ducts point. The most widely used framework, introduced by pathologist John McNeal, identifies four anatomic regions organized around the urethra as a central reference point.³

Peripheral zone: The largest region, making up over 70% of the glandular tissue. Its ducts fan out laterally from the urethra. This is where the vast majority of prostate cancers originate.
Central zone: About 25% of the glandular tissue, surrounding the ejaculatory ducts. Its cells look distinctly different from those in the peripheral zone under a microscope, hinting at biological differences that researchers still do not fully understand.
Transition zone: A small area flanking the urethra near the bladder neck. Despite its modest size in younger men, this is the zone that enlarges in benign prostatic hyperplasia (BPH) and can squeeze the urethra shut.
Periurethral glands: Tiny ducts clustered around the urethra that never fully develop into larger branching structures.

Understanding this zonal map matters clinically because the zone where a problem starts influences both symptoms and prognosis. A tumor growing in the peripheral zone, for example, can reach a considerable size before it presses on the urethra and causes urinary symptoms, which is one reason prostate cancer often has no early warning signs. A tumor starting in the transition zone, by contrast, tends to cause noticeable urinary obstruction earlier.

How Hormones Keep the Prostate Running

The prostate depends on androgens to grow, maintain itself, and carry out its secretory work. Testosterone circulating in the blood reaches the prostate and is converted locally into a more potent form called dihydrotestosterone (DHT) by an enzyme known as 5-alpha reductase.⁴ DHT is the primary driver of prostate cell growth and function. Without it, the prostate shrinks dramatically.

This hormonal arrangement includes a built-in amplification loop. Animal research has shown that DHT itself stimulates the production of the very enzyme that creates it, setting up a feed-forward cycle: a small amount of DHT triggers more enzyme activity, which produces more DHT, which drives further growth.⁵ This loop is essential during normal development, but it also helps explain why the prostate can keep growing throughout a man’s life, eventually causing problems.

Drugs that block 5-alpha reductase, such as finasteride, exploit this mechanism. In rat models, finasteride caused a 55% decrease in prostate weight and an 87% drop in the enzyme’s activity within a week.⁵ These drugs are now a mainstay of medical treatment for prostate enlargement in humans. Androgen regulation of 5-alpha reductase also works differently depending on the cell type within the prostate, which adds complexity to how treatments affect both normal tissue and cancerous tissue.⁶

The prostate’s development from the embryonic stage also depends on androgens. In all species studied, prostate formation follows a common pattern in which androgens drive the budding and branching of ducts from the urogenital sinus during fetal development.⁷ Without androgens at this critical window, a prostate simply does not form.

Benign Prostatic Hyperplasia

If you have heard of the prostate, it is probably because of BPH. This is the condition where the transition zone gradually enlarges over decades, pressing inward on the urethra and making it harder to urinate. BPH is not cancer and does not become cancer, but it is extremely common. The prevalence rises steeply with age, and by the time men reach their 70s and 80s, the majority will have at least some degree of it.

The cellular process behind BPH involves proliferation of both the glandular (epithelial) and structural (stromal) cells within the transition zone. Inflammation and sex hormones are thought to be key contributors to the process.⁸ Symptoms range from a weak urinary stream and frequent nighttime trips to the bathroom to, in severe cases, the inability to urinate at all. Treatment options include medications like alpha-blockers (which relax smooth muscle around the urethra) and 5-alpha reductase inhibitors (which shrink the gland), along with various surgical procedures for men who do not respond to drugs.

Metabolic health appears to play a role that many men do not expect. Research has found that metabolic syndrome, the cluster of conditions including abdominal obesity, high blood sugar, and abnormal cholesterol, is linked to larger prostate volumes and a higher likelihood of developing symptomatic BPH. One study found that all individual components of metabolic syndrome were positively associated with prostate volume, with abdominal obesity showing the strongest effect, and that having more components acted as a dose-dependent risk factor.⁹ Separately, inflammatory markers like TNF-alpha have been significantly correlated with BPH progression. Men with higher TNF-alpha levels had roughly double the rate of new BPH diagnoses over a four-year period compared to those with lower levels.¹⁰ The practical takeaway is that maintaining a healthy weight and managing blood sugar may benefit your prostate along with your heart.

Prostatitis and Chronic Pelvic Pain

Prostatitis, broadly defined as inflammation of the prostate, is one of the most common urological diagnoses in men under 50. It is classified into several categories, but the division that matters most for patients is between bacterial and non-bacterial forms. Acute and chronic bacterial prostatitis are caused by identifiable infections and typically respond well to antibiotics.¹¹

The far more common type, accounting for roughly 90% of prostatitis cases, is chronic pelvic pain syndrome (CP/CPPS). This condition presents with pain in the pelvic region, urinary difficulties, and sometimes pain during or after ejaculation, but no bacteria can be found on culture.¹² Whether CP/CPPS is truly a prostate disease, a nerve problem, a pelvic floor muscle issue, or some combination remains a matter of active debate. There is no uniformly effective treatment, and many men cycle through antibiotics, anti-inflammatory drugs, alpha-blockers, and physical therapy before finding something that helps. The condition can persist for years and significantly affects quality of life.

Emerging research has added a new layer to this picture by implicating the microbiome. Studies suggest that bacterial communities in the urinary tract, gut, and even the oral cavity may influence prostate inflammation in ways that standard culture techniques miss, potentially explaining why some men with “non-bacterial” prostatitis still seem to benefit from antimicrobial therapy.¹³

Prostate Cancer and the PSA Problem

Prostate cancer is among the most commonly diagnosed cancers in men worldwide, and the prostate’s zonal anatomy helps explain some of its clinical behavior. The majority of adenocarcinomas arise in the peripheral zone, though roughly 20% originate in the transition zone where BPH also develops.¹⁴ Because the peripheral zone sits at the back of the prostate near the rectum, tumors growing there can often be felt during a digital rectal exam before they cause symptoms. But many cancers are too small to feel, which is where PSA screening enters the story.

PSA is a protein produced by normal prostate cells. Its original biological role is to help liquefy semen. Cancer cells tend to release more PSA into the bloodstream, so elevated blood levels can signal trouble. The catch is that PSA is not specific to cancer. Levels also rise with BPH, prostatitis, recent sexual activity, and even physical trauma to the area.¹⁵ A systematic review of data from over 14,000 symptomatic patients found that while PSA testing was quite sensitive at detecting cancer (about 93%), it was poor at ruling it out in men who did not have cancer, with specificity of only about 20%.¹⁶ In practical terms, an elevated PSA catches most cancers, but it also flags many men who turn out not to have cancer at all.

Overdiagnosis is the other major concern. Some estimates suggest that 10% to 56% of cancers detected through PSA screening would never have caused symptoms or shortened a man’s life.¹⁵ For this reason, PSA’s most definitive role may be in monitoring men who have already been treated for prostate cancer, where rising levels after surgery reliably indicate recurrence.¹⁷ Multiparametric MRI has become an increasingly important complement to PSA, combining structural and functional imaging to help distinguish clinically significant tumors from harmless ones and to guide biopsies more accurately.

What Treatment Can Cost You

Treating prostate cancer often means grappling with difficult trade-offs. Radical prostatectomy, the surgical removal of the entire gland, is potentially curative but comes with real consequences. A nationwide observational study found that among men who were continent before treatment, about 15% reported urinary incontinence two years after surgery.¹⁸ The impact on sexual function is even more striking: among men who did not have erectile dysfunction before treatment, 87% reported it two years after prostatectomy. Even radiation therapy and watchful waiting were associated with worsened sexual function, though the rates were lower (41% and 46%, respectively).¹⁸

Hormone ablation therapy, which deprives the prostate of the androgens it needs, carries its own burden. Over 80% of men on hormone therapy report loss of erections within a year, along with a profound reduction in sexual desire.¹⁹ The degree of sexual recovery after surgery depends heavily on whether the nerve bundles running alongside the prostate were spared during the operation. Rates of erectile dysfunction after prostatectomy range widely, from about 30% when both nerve bundles are preserved to as high as 98% when neither is.¹⁹ These numbers underscore why shared decision-making between patient and urologist is so critical, especially for slow-growing cancers where active surveillance may be a reasonable alternative to immediate treatment.

Do Women Have a Prostate?

This might sound like a trick question, but the answer is essentially yes. The small glands clustered around the female urethra, historically called Skene’s glands or paraurethral glands, are the developmental equivalent of the male prostate. Both arise from the same embryonic tissue, the urogenital sinus, and they share key molecular markers. A study that serially sectioned the female urethra in patients ranging from newborns to 86-year-olds found paraurethral glands in nearly all specimens. Of those, 83% stained positive for prostate-specific antigen and 67% for prostatic acid phosphatase, the same proteins used to identify male prostate tissue.²⁰

Ultrastructural examination of these glands reveals cells strikingly similar to those in the male prostate, including tall secretory cells with active secretion features and basal reserve cells sitting beneath them.²¹ The homology is not limited to humans. In the plains viscacha, a South American rodent, researchers have described a well-developed female paraurethral gland with the structural hallmarks of a prostate, including glandular units surrounded by smooth muscle and secretory material in the lumen.²² The exact function of the female prostate is still debated, but its existence across species makes it clear that the prostate blueprint is not exclusively male. In rare cases, women can even develop conditions in these glands that mirror male prostate pathology, including cysts, infections, and, very rarely, adenocarcinoma that stains positive for PSA.

A Gland That Went Unrecognized for Centuries

Given how much clinical attention the prostate gets today, it is surprising how long it went without a clear identity in medical literature. Historians have traced the story back to ancient Greek anatomy, but for centuries the prostate was either unnamed or confused with other structures near the bladder neck. A pivotal early description is often attributed to the Italian anatomist Niccolò Massa in 1536, though Massa himself neither credited anyone before him nor claimed to be seeing something new. For centuries after, few anatomists treated the prostate as particularly noteworthy.²³ It was not until pathologists began linking the organ to urinary obstruction in aging men, and eventually to cancer, that the prostate gained the attention it holds in modern medicine. The gland’s habit of sitting quietly for decades before causing dramatic problems may explain, at least in part, why it took so long to become a focus of study.